---
title: "CanSino says China regulator accepts Menhycia label expansion filing to age 17"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293120449.md"
description: "CanSino Biologics announced that China's National Medical Products Administration (NMPA) has accepted its supplemental application to expand the age range for Menhycia, a meningococcal conjugate vaccine. The expansion aims to include children aged 3 months to 17 years, broadening the current approval which covers ages 3 months to 6 years."
datetime: "2026-07-19T10:08:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293120449.md)
  - [en](https://longbridge.com/en/news/293120449.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293120449.md)
generator: "portal-rs"
---

# CanSino says China regulator accepts Menhycia label expansion filing to age 17

-   CanSino Biologics received NMPA acceptance for a supplemental application to expand Menhycia’s indicated age range to 3 months–17 years. \* Menhycia, China’s first MCV4 meningococcal conjugate vaccine, is currently approved for children aged 3 months–6 years. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260719-12248943), on July 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [06185.HK](https://longbridge.com/en/quote/06185.HK.md)
- [688185.CN](https://longbridge.com/en/quote/688185.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline](https://longbridge.com/en/news/296024108.md)
- [CanSino says China regulator accepts NDA for TD5CP booster vaccine, grants priority review](https://longbridge.com/en/news/296020051.md)
- [CanSino’s Td5cp Booster Wins Priority Review After NDA Acceptance in China](https://longbridge.com/en/news/296020241.md)
- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)
- [CanSino Biologics says China NMPA approves adsorbed tetanus vaccine NDA](https://longbridge.com/en/news/296476562.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**